Granted Patent
B2
US 12,528,825 · App. 17/795,985 · Granted Jan 20, 2026
Compounds and uses thereof
Inventors:
Sabine K. Ruppel (Cambridge, MA); Zhaoxia Yang (Belmont, MA); Jason T. Lowe (East Bridgewater, MA); Johannes H. Voigt (Cambridge, MA)
Assignee:
FOGHORN THERAPEUTICS INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
Claims (20)
1 . A compound having the structure:
or a pharmaceutically acceptable salt thereof.
2 . A pharmaceutical composition comprising a compound having the structure:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
3 . A method of inhibiting the level and/or activity of BRD9 in a cell, the method involving contacting the cell with an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
4 . The method of claim 3 wherein the cell is a cancer cell.
5 . The method of claim 4 , wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.
6 . The method of claim 5 , wherein the cancer is a sarcoma.
7 . The method of claim 6 , wherein the sarcoma is a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, or low-grade rhabdomyosarcoma.
8 . The method of claim 7 , wherein the sarcoma is synovial sarcoma.
9 . A method of treating a BAF complex-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
10 . A method of treating an SS18-SSX fusion protein-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
11 . A method of treating a BRD9-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
12 . The method of claim 9 , wherein the disorder is cancer or an infection.
13 . A method of treating a cancer in a subject in need thereof, the method including administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
14 . The method of claim 13 , wherein the cancer is a malignant, rhabdoid tumor, a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, a sarcoma, non-small cell lung cancer, stomach cancer, or breast cancer.
15 . The method of claim 14 , wherein the cancer is a sarcoma.
16 . The method of claim 15 , wherein the sarcoma is a soft tissue sarcoma, synovial sarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, clear cell sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibromyxoid sarcoma, gastrointestinal stromal tumor, Kaposi sarcoma, liposarcoma, leiomyosarcoma, malignant mesenchymoma malignant peripheral nerve sheath tumors, myxofibrosarcoma, or low-grade rhabdomyosarcoma.
17 . The method of claim 16 , wherein the sarcoma is synovial sarcoma.
18 . A method of treating infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
Continuity (2)
Provisional Application
62967525
· Jan 29, 2020
References Cited (213)
US 5858358A
· June et al.
· 1999
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 6352694B1
· June et al.
· 2002
[cited by applicant]
US 6534055B1
· June et al.
· 2003
[cited by applicant]
US 6692964B1
· June et al.
· 2004
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6887466B2
· June et al.
· 2005
[cited by applicant]
US 6905680B2
· June et al.
· 2005
[cited by applicant]
US 6905681B1
· June et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7056883B2
· Ito et al.
· 2006
[cited by applicant]
US 7067318B2
· June et al.
· 2006
[cited by applicant]
US 7144575B2
· June et al.
· 2006
[cited by applicant]
US 7172869B2
· June et al.
· 2007
[cited by applicant]
US 7175843B2
· June et al.
· 2007
[cited by applicant]
US 7205103B2
· Emerson
· 2007
[cited by applicant]
US 7232566B2
· June et al.
· 2007
[cited by applicant]
US 7572631B2
· Berenson et al.
· 2009
[cited by applicant]
US 8476434B2
· Geuns-Meyer et al.
· 2013
[cited by applicant]
US 9271978B2
· Liu et al.
· 2016
[cited by applicant]
US 9353051B2
· Byrd et al.
· 2016
[cited by applicant]
US 9410943B2
· Kadoch et al.
· 2016
[cited by applicant]
US 9708338B2
· Yukimasa et al.
· 2017
[cited by applicant]
US 9718821B2
· Woods et al.
· 2017
[cited by applicant]
US 9908885B2
· Bennett et al.
· 2018
[cited by applicant]
US 9919998B2
· Ebright et al.
· 2018
[cited by applicant]
US 20050079512A1
· Emerson et al.
· 2005
[cited by applicant]
US 20110053897A1
· Che et al.
· 2011
[cited by applicant]
US 20110061116A1
· Haldar et al.
· 2011
[cited by applicant]
US 20160058872A1
· Crew et al.
· 2016
[cited by applicant]
US 20180085465A1
· Bradner et al.
· 2018
[cited by applicant]
US 20190076539A1
· Phillips et al.
· 2019
[cited by applicant]
US 20200206344A1
· Kadoch et al.
· 2020
[cited by applicant]
US 20210198256A1
· Nasveschuk et al.
· 2021
[cited by applicant]
US 20210290676A1
· Chaudhary
· 2021
[cited by applicant]
US 20220193205A1
· Zhou et al.
· 2022
[cited by applicant]
US 20220265618A1
· Malatesta et al.
· 2022
[cited by applicant]
US 20220315578A1
· Chen et al.
· 2022
[cited by applicant]
US 20230065463A1
· Ruppel
· 2023
[cited by examiner]
US 20230066136A1
· Ruppel et al.
· 2023
[cited by applicant]
US 20230142883A1
· Ruppel et al.
· 2023
[cited by applicant]
US 20230331722A1
· Ruppel et al.
· 2023
[cited by applicant]
US 20240002382A1
· Ruppel et al.
· 2024
[cited by applicant]
US 20240067642A1
· Ruppel et al.
· 2024
[cited by applicant]
US 20240150328A1
· Zhou et al.
· 2024
[cited by applicant]
US 20240150348A1
· Ruppel et al.
· 2024
[cited by applicant]
US 20240166668A1
· Ruppel et al.
· 2024
[cited by applicant]
US 20240190894A1
· Gu et al.
· 2024
[cited by applicant]
US 20240325370A1
· Chen et al.
· 2024
[cited by applicant]
US 20250085300A1
· Huang et al.
· 2025
[cited by applicant]
CN 107056772A
· 2017
[cited by applicant]
CN 108690020A
· 2018
[cited by applicant]
JP 07033773A
· 1995
[cited by applicant]
WO WO2011014515A1
· 2011
[cited by applicant]
WO WO2013126656A1
· 2013
[cited by applicant]
WO WO2016051187A1
· 2016
[cited by examiner]
WO WO2016133935A1
· 2016
[cited by applicant]
WO WO2017197051A1
· 2017
[cited by applicant]
WO WO2017197056A1
· 2017
[cited by applicant]
WO WO2017223452A1
· 2017
[cited by applicant]
WO WO2018102725A1
· 2018
[cited by applicant]
WO WO2018177297A1
· 2018
[cited by applicant]
WO WO2019099868A2
· 2019
[cited by applicant]
WO WO2019152437A1
· 2019
[cited by applicant]
WO WO2019152440A1
· 2019
[cited by applicant]
WO WO2019195201A1
· 2019
[cited by applicant]
WO WO2019207538A1
· 2019
[cited by applicant]
WO WO2020051235A1
· 2020
[cited by applicant]
WO WO2020078933A1
· 2020
[cited by applicant]
WO WO2020132561A1
· 2020
[cited by applicant]
WO WO2020160192A1
· 2020
[cited by applicant]
WO WO2020160198A1
· 2020
[cited by applicant]
WO WO2020160193A2
· 2020
[cited by examiner]
WO WO2020239103A1
· 2020
[cited by applicant]
WO WO2020264177A1
· 2020
[cited by applicant]
WO WO2021055295A1
· 2021
[cited by applicant]
WO WO2021155225A1
· 2021
[cited by applicant]
WO WO2021178920A1
· 2021
[cited by applicant]
WO WO2023283263A1
· 2023
[cited by applicant]
WO WO2023039208A1
· 2023
[cited by applicant]
WO WO2023200800A1
· 2023
[cited by applicant]
WO WO2024006292A2
· 2024
[cited by applicant]
WO WO2024013766A1
· 2024
[cited by applicant]
WO WO2024013812A1
· 2024
[cited by applicant]
WO WO2024014021A1
· 2024
[cited by applicant]
WO WO2024037578A1
· 2024
[cited by applicant]
WO WO2024163609A1
· 2024
[cited by applicant]
WO WO2024163641A2
· 2024
[cited by applicant]
WO WO2024163751A1
· 2024
[cited by applicant]
WO WO2025015149A2
· 2025
[cited by applicant]
WO WO2025015152A1
· 2025
[cited by applicant]
Merriam-Webster, definition of isomer, obtained from https://www.merriam-webster.com/dictionary/isomer on Mar. 31, 2025 (Year: 2025).
[cited by examiner]
Dorwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag Gmbh & Co. KGaA, 2005, Preface (Year: 2005).
[cited by examiner]
U.S. Appl. No. 17/245,379, Sandoval et al..
[cited by applicant]
U.S. Appl. No. 17/425,013, Ruppel et al.
[cited by applicant]
U.S. Appl. No. 17/425,132, Ruppel et al.
[cited by applicant]
U.S. Appl. No. 17/425,153, Ruppel et al.
[cited by applicant]
U.S. Appl. No. 17/696,656, Ruppel et al.
[cited by applicant]
Baheti et al., “Excipients used in lyophilization of small molecules,” J. Excipients and Food Chem. 1(1):41-54 (2010).
[cited by applicant]
Börold et al., “BRD9 is a druggable component of interferon-stimulated gene expression and antiviral activity,” EMBO Rep. 22(10):e52823 (Aug. 16, 2021) (18 pages).
[cited by applicant]
Brien et al, Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma,eLIFE. 7:1-26 (2018).
[cited by applicant]
Crawford et al., “Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance,” Bioorg Med Chem Lett. 27(15):3534-41(2017).
[cited by applicant]
Extended European Search Report for European Patent Application No. 20749033.5, dated Sep. 29, 2022 (5 pages).
[cited by applicant]
Hay et al., “Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains,” Medchemcomm. 6:1381-86 (2015).
[cited by applicant]
Hohmann et al., “Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition,” Nat Chem Biol. 12(9): 672-679 (2016) (12 pages).
[cited by applicant]
Hu et al., “Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment,” Nat Commun. 10(1):733 (2019) (17 pages).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/015740, issued Jul. 27, 2021 (6 pages).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/044508, issued Feb. 1, 2022 (6 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/44043, mailed Nov. 9, 2020 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/44508, mailed Jan. 12, 2021 (9 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/015740, mailed Jun. 26, 2020 (11 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/15630, mailed Apr. 8, 2021 (8 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/36252, mailed Nov. 15, 2022 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/38641, mailed Nov. 17, 2022 (10 pages).
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US21/15813, mailed Apr. 6, 2021 (24 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/028511, mailed Aug. 1, 2022 (14 pages).
[cited by applicant]
Kadoch et al., “Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics,” Sci Adv. 1(5):e1500447 (2015) (17 pages).
[cited by applicant]
Kadoch et al., “Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy,” Nat Genet. 45(6):592-601 (2013) (11 pages).
[cited by applicant]
Kadoch et al., “Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma,” Cell. 153(1):71-85 (2013).
[cited by applicant]
Kotla et al., “Mechanism of action of lenalidomide in hematological malignancies,” J Hematol Oncol. 2:36 (Aug. 12, 2009).
[cited by applicant]
Martin et al., “Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor,” J Med Chem. 59(10):4462-75 (2016).
[cited by applicant]
McBride et al., “Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities,” J Pathol. 244(5): 638-649 (2018).
[cited by applicant]
Michel et al., “Abstract PR15: BRD9 defines a novel mammalian SWI/SNF (BAF) complex configuration which supports proliferation in AML,” Clin Cancer Res. 23(24):PR15 (2017) (4 pages).
[cited by applicant]
Pan et al., “A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing,” Science. 359(6377):770-75 (2018) (11 pages).
[cited by applicant]
Picaud et al., “9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain,” J Med Chem. 58(6):2718-36 (2015).
[cited by applicant]
PubChem CID 68310947, “7-Methyl-4-phenyl-2H-isoquinolin-1-one,” created Nov. 30, 2012 (8 pages).
[cited by applicant]
Remillard et al., “Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands,” Angew Chem Int Ed Engl. 56(21):5738-43 (2017) (7 pages).
[cited by applicant]
Remillard et al., “Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands,” available in PMC May 24, 2018, published in final edited form as: Angew Chem Int Ed Engl. 56(21):5738-5743 (2017) (14 pages).
[cited by applicant]
Teuscher et al., “A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors,” J Med Chem. 60(1): 157-169 (2017).
[cited by applicant]
Theodoulou et al., “Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition,” J Med Chem. 59(4):1425-39 (2015).
[cited by applicant]
Vangamudi et al., “The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies,” Cancer Res. 75(18):3865-78 (2015).
[cited by applicant]
Wang et al., “NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains,” Chembiochem. 17(15):1456-63 (2016).
[cited by applicant]
Zhu et al., “Targeting BRD9 for Cancer Treatment: A New Strategy,” Onco Targets Ther. 13:13191-13200 (Dec. 24, 2020).
[cited by applicant]
Zoppi et al., “Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 a…
[cited by applicant]
“Acute Leukemia,” Merck Manual (Online Edition), retrieved Jul. 10, 2013 (6 pages).
[cited by applicant]
Al-Hamdany et al., “Synthesis, structural characterization and antibacterial evaluation of some new 2-pyrazoline derivatives”. World Journal of Pharmacy and Pharmaceutical Sciences. 7(11):200-211 (2018).
[cited by applicant]
Amako et al., “Development and Advances of PROTACs: Induced Protein Degradation by Hijacking Ubiquitin Ligase,” Journal of Synthetic Organic Chemistry, Japan 76(4):358-9 (2018). English abstract included.
[cited by applicant]
Ballatore et al., “Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties,” Bioorg Med Chem. 20(14):4451-61 …
[cited by applicant]
Bondeson et al., “Targeted Protein Degradation by Small Molecules,” Annu Rev Pharmacol Toxicol. 57:107-23 (Epub Oct. 2016) (Jan. 2017).
[cited by applicant]
Che et al., “Inducing protein-protein interactions with molecular glues,” Bioorg Med Chem Lett. 28(15):2585-92 (Aug. 2018) (18 pages).
[cited by applicant]
Choi et al., “Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new comput…
[cited by applicant]
Croce, “Oncogenes and cancer,” N Engl J Med. 358(5):502-11 (Jan. 31, 2008).
[cited by applicant]
Cui et al., “The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming,” Mol Cell Biol. 24(10):4476-86 (May 2004).
[cited by applicant]
Fligiel et al., “Protein degradation following treatment with hydrogen peroxide,” Am J Pathol. 115(3):418-25 (Jun. 1984).
[cited by applicant]
Gura, “Systems for identifying new drugs are often faulty,” Science. 278(5340):1041-2 (1997).
[cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials,” Br J Cancer. 84(10):1424-31 (2001).
[cited by applicant]
Khaminets et al., “Ubiquitin-Dependent And Independent Signals In Selective Autophagy,” Trends Cell Biol. 26(1):6-16 (Jan. 2016).
[cited by applicant]
Krämer et al., “BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors,” Int J Mol Sci. 18(7):1537 (Jul. 16, 2017) (12 pages).
[cited by applicant]
Lopez-Girona et al. “Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide,” Leukemia. 26(11):2326-2335 (2012).
[cited by applicant]
Muscal et al., “Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates,” Available in PMC Jun. 18, 2013. Published in final edited form as: Cancer Chemother Pharmacol. 69(4)…
[cited by applicant]
Pearce et al., Chapter 18: Failure modes in anticancer drug discovery and development. Cancer Drug Design and Discovery. Stephen Neidle, 424-435 (2008).
[cited by applicant]
PubChem CID 12097004 “7-Phenyl-5H-furo[3,2-c]pyridin-4-one,” created Feb. 7, 2007, retrieved Apr. 28, 2020 (9 pages).
[cited by applicant]
Simone, “Oncology: Introduction,” Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, (1996) (8 pages).
[cited by applicant]
Supporting Information for Remillard et al., “Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands,” Angew Chem Int Ed Engl. 56(21):5738-43 (2017) (43 pages).
[cited by applicant]